Cargando…

Effect of Intravitreal Bevacizumab on Vascular Endothelial Growth Factor Expression in Patients with Proliferative Diabetic Retinopathy

PURPOSE: To investigate the effect of bevacizumab (Avastin; Genentech, San Francisco, CA, USA) on vascular endothelial growth factor (VEGF) expression and inflammation in fibrovascular membranes in patients with proliferative diabetic retinopathy (PDR). MATERIALS AND METHODS: Fibrovascular membranes...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Eun Jee, Kang, Shin Jeong, Koo, Ja Seung, Choi, Yoon Jung, Grossniklaus, Hans E., Koh, Hyoung Jun
Formato: Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017691/
https://www.ncbi.nlm.nih.gov/pubmed/21155048
http://dx.doi.org/10.3349/ymj.2011.52.1.151
_version_ 1782195933749968896
author Chung, Eun Jee
Kang, Shin Jeong
Koo, Ja Seung
Choi, Yoon Jung
Grossniklaus, Hans E.
Koh, Hyoung Jun
author_facet Chung, Eun Jee
Kang, Shin Jeong
Koo, Ja Seung
Choi, Yoon Jung
Grossniklaus, Hans E.
Koh, Hyoung Jun
author_sort Chung, Eun Jee
collection PubMed
description PURPOSE: To investigate the effect of bevacizumab (Avastin; Genentech, San Francisco, CA, USA) on vascular endothelial growth factor (VEGF) expression and inflammation in fibrovascular membranes in patients with proliferative diabetic retinopathy (PDR). MATERIALS AND METHODS: Fibrovascular membranes from 19 eyes of 18 patients with PDR were studied using immunohistochemistry and analyzed in the following 3 groups; group 1: 4 inactive PDR eyes, group 2: 10 active PDR eyes treated preoperatively with adjunctive intravitreal bevacizumab, group 3: five active PDR eyes not treated preoperatively with bevacizumab. Immunohistochemical staining for VEGF, CD31 and CD68 were done. RESULTS: The immunoreactivity to VEGF and CD 31-positive blood vessels was significantly higher in membranes from group 3 than group 1 (p = 0.007 for VEGF, 0.013 for CD 31-positive vessels). Intravitreal bevacizumab caused a reduction in VEGF expression and vascular densities in 4 out of 10 (40%) excised membranes from eyes with PDR. However, six membranes (60%) in group 2 still demonstrated relatively strong VEGF expression and high vascular density. Infiltration of macrophages was observed in 16 out of the 19 membranes, and the density of macrophages was increased in group 2 compared with group 1 (p = 0.043). CONCLUSION: Intravitreal bevacizumab injections caused some reduction in VEGF expression and vascular densities in a limited number of active PDR patients. A single intravitreal bevacizumab injection may not be enough to induce complete blockage of VEGF and pathologic neovascularization in active PDR patients. Repeated injections, panretinal photocoagulation and/or PPV may be necessary following intravitreal bevacizumab to reinforce the anti-VEGF effect of the drug.
format Text
id pubmed-3017691
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Yonsei University College of Medicine
record_format MEDLINE/PubMed
spelling pubmed-30176912011-01-10 Effect of Intravitreal Bevacizumab on Vascular Endothelial Growth Factor Expression in Patients with Proliferative Diabetic Retinopathy Chung, Eun Jee Kang, Shin Jeong Koo, Ja Seung Choi, Yoon Jung Grossniklaus, Hans E. Koh, Hyoung Jun Yonsei Med J Original Article PURPOSE: To investigate the effect of bevacizumab (Avastin; Genentech, San Francisco, CA, USA) on vascular endothelial growth factor (VEGF) expression and inflammation in fibrovascular membranes in patients with proliferative diabetic retinopathy (PDR). MATERIALS AND METHODS: Fibrovascular membranes from 19 eyes of 18 patients with PDR were studied using immunohistochemistry and analyzed in the following 3 groups; group 1: 4 inactive PDR eyes, group 2: 10 active PDR eyes treated preoperatively with adjunctive intravitreal bevacizumab, group 3: five active PDR eyes not treated preoperatively with bevacizumab. Immunohistochemical staining for VEGF, CD31 and CD68 were done. RESULTS: The immunoreactivity to VEGF and CD 31-positive blood vessels was significantly higher in membranes from group 3 than group 1 (p = 0.007 for VEGF, 0.013 for CD 31-positive vessels). Intravitreal bevacizumab caused a reduction in VEGF expression and vascular densities in 4 out of 10 (40%) excised membranes from eyes with PDR. However, six membranes (60%) in group 2 still demonstrated relatively strong VEGF expression and high vascular density. Infiltration of macrophages was observed in 16 out of the 19 membranes, and the density of macrophages was increased in group 2 compared with group 1 (p = 0.043). CONCLUSION: Intravitreal bevacizumab injections caused some reduction in VEGF expression and vascular densities in a limited number of active PDR patients. A single intravitreal bevacizumab injection may not be enough to induce complete blockage of VEGF and pathologic neovascularization in active PDR patients. Repeated injections, panretinal photocoagulation and/or PPV may be necessary following intravitreal bevacizumab to reinforce the anti-VEGF effect of the drug. Yonsei University College of Medicine 2011-01-01 2010-11-30 /pmc/articles/PMC3017691/ /pubmed/21155048 http://dx.doi.org/10.3349/ymj.2011.52.1.151 Text en © Copyright: Yonsei University College of Medicine 2011 http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Chung, Eun Jee
Kang, Shin Jeong
Koo, Ja Seung
Choi, Yoon Jung
Grossniklaus, Hans E.
Koh, Hyoung Jun
Effect of Intravitreal Bevacizumab on Vascular Endothelial Growth Factor Expression in Patients with Proliferative Diabetic Retinopathy
title Effect of Intravitreal Bevacizumab on Vascular Endothelial Growth Factor Expression in Patients with Proliferative Diabetic Retinopathy
title_full Effect of Intravitreal Bevacizumab on Vascular Endothelial Growth Factor Expression in Patients with Proliferative Diabetic Retinopathy
title_fullStr Effect of Intravitreal Bevacizumab on Vascular Endothelial Growth Factor Expression in Patients with Proliferative Diabetic Retinopathy
title_full_unstemmed Effect of Intravitreal Bevacizumab on Vascular Endothelial Growth Factor Expression in Patients with Proliferative Diabetic Retinopathy
title_short Effect of Intravitreal Bevacizumab on Vascular Endothelial Growth Factor Expression in Patients with Proliferative Diabetic Retinopathy
title_sort effect of intravitreal bevacizumab on vascular endothelial growth factor expression in patients with proliferative diabetic retinopathy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017691/
https://www.ncbi.nlm.nih.gov/pubmed/21155048
http://dx.doi.org/10.3349/ymj.2011.52.1.151
work_keys_str_mv AT chungeunjee effectofintravitrealbevacizumabonvascularendothelialgrowthfactorexpressioninpatientswithproliferativediabeticretinopathy
AT kangshinjeong effectofintravitrealbevacizumabonvascularendothelialgrowthfactorexpressioninpatientswithproliferativediabeticretinopathy
AT koojaseung effectofintravitrealbevacizumabonvascularendothelialgrowthfactorexpressioninpatientswithproliferativediabeticretinopathy
AT choiyoonjung effectofintravitrealbevacizumabonvascularendothelialgrowthfactorexpressioninpatientswithproliferativediabeticretinopathy
AT grossniklaushanse effectofintravitrealbevacizumabonvascularendothelialgrowthfactorexpressioninpatientswithproliferativediabeticretinopathy
AT kohhyoungjun effectofintravitrealbevacizumabonvascularendothelialgrowthfactorexpressioninpatientswithproliferativediabeticretinopathy